中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
NASH
Viral Hepatitis
HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
Investors
Financials & Filing
Presentation Materials
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
2021-03-03
Voluntary Announcement - Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-beta Agonist ASC41 For NASH
2021-02-25
Voluntary Announcement - Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-Beta Agonist ASC41 Data Further Confirmed Doses for Phase II Trial in Patients with NASH
2021-02-21
Voluntary Announcement - Participation in Sagimet’S US$80 Million in Crossover Financing with Premium Investors
2021-02-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
2021-02-02
Change of Registered Office, Principal Share Registrar and Transfer Office in the Cayman Islands
2021-02-01
Next Day Disclosure Returns - Others
2021-01-14
Voluntary Announcement - Gannex Announces Positive Phase I Clinical Results on Its THR-beta Agonist ASC41
2021-01-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
2021-01-05
Grant of Share Options
2020-12-31
1
2
3
4
»